Vigabatrin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Vigabatrin
Vigabatrin: Known uses and market status in Australia
Summary
The TxGNN deep-learning model produced candidates for Vigabatrin, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use found among the candidates is recorded in the knowledge graph, with no approval found.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| West syndrome |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13919N | Sabril | Tablet 500 mg | Valid |
Safety Considerations
- Knowledge-graph contraindication signals (not label text): kidney disease, pyoureter, congestive heart failure, peripheral nervous system disease, peripheral neuropathy, anaemia, macrocytic anaemia and scotoma.
- Drug Interactions (65 recorded in total; examples):
- Major: systemic and topical corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone), deferoxamine, and topical oxyquinoline.
- Moderate: opioids (morphine, opium, diphenoxylate, difenoxin), cannabinoids (dronabinol, nabilone), metoclopramide, sibutramine and ethanol.
- Other considerations from the prediction data: vigabatrin is known for retinal toxicity (visual field defects) and reversible MRI changes (VABAM), which are particularly relevant in infants (see PMID 41004695).
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.